ABSCF

Quote

Short

News

Articles

Message Board

Ab Science (OTCMKTS : ABSCF ) News

Ab Science (OTCMKTS: ABSCF) News Releases

ABSCF News Releases

June 02, 2026 12:05:19 pm

GlobeNewswire

AB Science : Stonegate Capital Partners updates its coverage of AB Science's stock with a target price of EUR 4.25 per share

May 25, 2026 12:06:43 pm

GlobeNewswire

AB Science announces that its stock continues to be covered by Maxim Group, with a target price of Euro4.00 per share

May 13, 2026 01:36:33 pm

GlobeNewswire

AB Science reports its revenues for the year 2025 and provides an update on its activities

April 27, 2026 12:06:54 pm

GlobeNewswire

AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors

April 20, 2026 03:32:18 pm

GlobeNewswire

AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients

April 16, 2026 01:20:13 pm

GlobeNewswire

AB Science provides an update on its clinical development program.

February 24, 2026 12:02:28 pm

GlobeNewswire

AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS

February 09, 2026 12:04:45 pm

GlobeNewswire

AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors

January 29, 2026 12:00:56 pm

GlobeNewswire

AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer

January 21, 2026 12:02:18 pm

GlobeNewswire

AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account